Status:
UNKNOWN
Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Ex vivo organotypic tumor slice cultures (OTSC) have unique characteristics in terms of tissue processing time and the maintenance of original microenvironment. Moreover, drug screening has been succe...
Detailed Description
Most patients with ovarian cancer (OC) present with advanced stage and severe symptoms. The standard of care is based on an association between surgery and platinum-based chemotherapy, to which target...
Eligibility Criteria
Inclusion
- Preoperative clinical, serological and radiologic suspicion of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or greater ovarian, fallopian tube, or primary peritoneal cancer;
- Age over 18 years;
- Estimated life expectancy of at least 4 weeks;
- Fagotti score (PIV) \> 8 or patients not considered operable in the first place for any reasons;
- Histologic diagnoses of epithelial ovarian cancer at frozen section.
Exclusion
- Non- epithelial histology at frozen section;
- Patients enrolled in other clinical trials.
Key Trial Info
Start Date :
September 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 13 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06065358
Start Date
September 13 2021
End Date
December 13 2023
Last Update
October 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy